Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
Canada, US Hold Constructive Trade Talks as Tariff Negotiations Continue 
China Inflation Cools in July as CPI Misses Forecast, PPI Deflation Eases 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Asian Stocks Mixed as Chip Selloff Hits KOSPI, Nikkei Ahead of US Jobs Data 
US Dollar Falls as Weak July Jobs Report Dents Fed Rate Hike Bets 
Trump Unveils $3 Billion U.S. Critical Minerals Push 
Gold Prices Steady as Hormuz Tensions Fuel Fed Rate Concerns 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Oil Prices Set for Steep Weekly Losses as Hormuz Deal Stalls 
US Job Growth Seen Picking Up in July 
Samsung Biologics, South Korea's biotech behemoth, expands its portfolio in a $1.08 billion deal with U.S. pharma titan, Pfizer, marking a landmark in global biotech manufacturing. The enhanced partnership will leverage Samsung's newest facility to produce Pfizer's multiproduct biosimilar portfolio.
This includes a new contract signed with Pfizer, building upon the initial deal established in March. Under the new agreement, Samsung Biologics will manufacture an additional $193 million of Pfizer products.
Additionally, Samsung Biologics will produce Pfizer's multiproduct biosimilar portfolio, encompassing oncology, inflammation, and immunotherapy, with a value of $704 million. The company will extend its manufacturing capabilities to provide Pfizer ample capacity for large-scale production of a multiproduct biosimilar portfolio.
This strategic collaboration will occur at Samsung Biologics' newest facility, Plant 4, in Songdo, South Korea. Completing the 240,000-liter biomanufacturing plant in June 2023 marks a significant milestone in the continued growth of Samsung Biologics.
Mike McDermott, Chief Global Supply Officer and Executive Vice President at Pfizer, expressed his enthusiasm for the partnership, stating they are pleased to extend the strategic collaboration with Pfizer as we share and support their strong vision to bring innovative solutions for patients around the globe.
These manufacturing partnerships solidify Samsung Biologics' position in the global contract development and manufacturing organization (CDMO) market. As part of its expansion strategy, the company is increasing its production capacity and aims to become a major player in the industry.
The contracts with Pfizer highlight the long-term strategic partnership between the two companies, further establishing Samsung Biologics as a trusted collaborator. The company plans to explore new avenues in overseas markets by considering opening new sales offices to facilitate communication with global customers. With an existing office in New Jersey and a research and development center in San Francisco, Samsung Biologics is set for continued growth on a global scale.
